CHEIRON study docetaxel plus enzalutamide versus docetaxel as firstline chemotherapy for patients with mCRPC

CHEIRON study: docetaxel plus enzalutamide versus docetaxel as first-line chemotherapy for patients with mCRPC

17:13 EST 14 Feb 2019 | ecancermedicalscience

Dr Caffo Orazio speaks to ecancer at the 2019 ASCO Genitourinary Cancers Symposium about the CHEIRON study looking into docetaxel plus enzalutamide versus docetaxel as first-line chemotherapy for patients with mCRPC. He discusses the positive findings...

More From BioPortfolio on "CHEIRON study: docetaxel plus enzalutamide versus docetaxel as first-line chemotherapy for patients with mCRPC"